NeuroSense Therapeutics Ltd. (NRSNW)
NCM
Closing price as of 2026-09-02 · Source: TEK2day Finance
Key Metrics
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Quarterly Financials
| Metric | 2024-09-30 | 2024-12-31 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Operating Income | (2.1M) | (1.8M) |
| Net Income | (2.1M) | (1.8M) |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.6M) | (12.0M) | (9.9M) | (11.1M) |
| Net Income | (10.5M) | (10.1M) | (10.2M) | (11.1M) |